Janos L. Tanyi
Janos L. Tanyi
Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Attending Physician, Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
Department: Obstetrics and Gynecology
Contact information
Department of Obstetrics and Gynecology
Jordan Center for Gynecologic Cancer at Penn
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard, 3 West
Philadelphia, PA 19104
Jordan Center for Gynecologic Cancer at Penn
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard, 3 West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Fax: 215-349-5849
Email:
janos.tanyi@uphs.upenn.edu
janos.tanyi@uphs.upenn.edu
Education:
M.D. (Summa cum Laude)
University of Debrecen, Faculty of Medicine, Hungary , 1993.
Ph.D. (Summa cum Laude)
Semmelweis University, Faculty of Medicine, School of Clinical Sciences, Budapest, Hungary, 2008.
M.D. (Summa cum Laude)
University of Debrecen, Faculty of Medicine, Hungary , 1993.
Ph.D. (Summa cum Laude)
Semmelweis University, Faculty of Medicine, School of Clinical Sciences, Budapest, Hungary, 2008.
Post-Graduate Training
Residency Training, Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary, 1993-1998.
Postdoctoral Fellow and Research Scholar, University of Texas, MD Anderson Cancer Center, Houston, TX, 1999-2004.
Resident, Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, 2004-2008.
Fellow, Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2008-2011.
Permanent linkResidency Training, Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary, 1993-1998.
Postdoctoral Fellow and Research Scholar, University of Texas, MD Anderson Cancer Center, Houston, TX, 1999-2004.
Resident, Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, 2004-2008.
Fellow, Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2008-2011.
Selected Publications
Dagher C, Huang A, Nasioudis D, Giuntoli II RL, Latif NA, Tanyi JL, Kim SH, Ko EM, Gysler SM, Martin LP: Clinical Activity of Metronomic Cyclophosphamide and Bevacizumabwithor without Pembrolizumab in Recurrent Ovarian Cancer: A Single-Institution Retrospective Analysis. SGO Annual Meeting, San Juan PR Apr 2026.Pavlatos E, Tate B, Nguyen A, Heller IS, Nasioudis D, Tanyi JL, Torigian DA, Rodriguez D, Domchek SM, Drapkin RI, Brown EJ, Mills GB, Simpkins F: Increased immune activity in patients with high-grade serious ovarian cancer after combination PARPi + ATRi therapy. AACR Annual Meeting, San Diego, CA Apr 2026.
Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi JL, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek SM, Zhang L, Hu X: Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. bioRxiv Page: 13:RP99225. doi: 10.7554/eLife.99225, Feb 2026.
Hu X, Huang J, Yuan J, Sun Y, Wang Y, Hu Z, Jiang J, Wang Z, Wang B, Long M, Maxwell KN, Fan Y, Tanyi JL, Montone KT, Li H, Kim SH, Nathanson KL, Rebbeck TR, Domchek SM, Vonderheide RH, Zhang L: Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell Rep Page: 45(2):116882. doi: 10.1016/j.celrep.2025, Feb 2026.
Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi J, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek S, Zhang L, Hu X: Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. Elife Page: 13:RP99225. doi: 10.7554/eLife.99225, Feb 2026.
Barber-Rotenberg JS, Haas AR, Aggarwal C, O'Hara M, Hexner E, Pequignot E, Dowd E, Ndeupen S, Thai E, Chen F, Oner BS, Czuczman C, Gonzalez VE, Fraietta JA, Hwang WT, Chew A, Jadlowsky JK, Marshall A, Shea KM, Jiang Y, Cosey A, Ferthio R, Levine BL, Plesa G, Siegel DL, Young RM, Sheppard NC, Albelda SM, June CH, Tanyi JL: Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers. Mol Ther. Page: S1525-0016(26)00022-5. doi: 10.1016/j.ymthe.2026.01.021, Jan 2026.
Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O'Hara MH: Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Cell Rep Med. Page: 6(9):102301. doi: 10.1016/j.xcrm.2025.102301, Sep 2025.
Ghisoni E, Benedetti F, Minasyan A, Desbuisson M, Cunnea P, Grimm AJ, Fahr N, Capt C, Rayroux N, De Carlo F, Gulhan DC, Dagher J, Barras D, Morotti M, Marín-Jiménez JA, Chap BS, Santoro T, Spagnol G, Fleury M, Fortis K, Dorier J, Townsend MK, Tissot S, Rusakiewicz S, Ferreira HJ, Kraemer AI, Bassani-Stenberg M, Swisher EM, Kandalaft LA, Mastroyannis SA, Montone KT, Powell DJ Jr, Banerjee S, Terry KL, Tworoger SS, Pittet MJ, Tanyi JL, Coukos G, Merritt MA, Fotopoulou C, Conejo-Garcia JR, Laniti DD: Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. .Cancer Cell Page: 43(8):1568-1586.e10. doi: 10.1016, Aug 2025.
Gleason E, Pollie M, Satish S, Li S, Tanyi JL: Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report. Gynecol Oncol Rep Page: 60:101816. doi: 10.1016/j.gore.2025.101816, Aug 2025.
Sande CM, Erráez-Jaramillo PJ, Zhang Q, Suresh K, Hicks-Courant K, Tanyi JL, Zhang PJ.: Giant Angiomyofibroblastoma With a Florid Lipomatous Component: A Report and Review of Diagnostic Considerations. Int J Surg Pathol Page: 33(4):921-927. doi: 10.1177/10668969241291890, Jun 2025.